EA032717B1 - Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол - Google Patents

Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол Download PDF

Info

Publication number
EA032717B1
EA032717B1 EA201692398A EA201692398A EA032717B1 EA 032717 B1 EA032717 B1 EA 032717B1 EA 201692398 A EA201692398 A EA 201692398A EA 201692398 A EA201692398 A EA 201692398A EA 032717 B1 EA032717 B1 EA 032717B1
Authority
EA
Eurasian Patent Office
Prior art keywords
resveratrol
diseases
fatty acids
composition according
pufas
Prior art date
Application number
EA201692398A
Other languages
English (en)
Russian (ru)
Other versions
EA201692398A1 (ru
Inventor
Джузеппе Джаннини
Мозе Сантаньелло
Original Assignee
Альфасигма С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альфасигма С.П.А. filed Critical Альфасигма С.П.А.
Publication of EA201692398A1 publication Critical patent/EA201692398A1/ru
Publication of EA032717B1 publication Critical patent/EA032717B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
EA201692398A 2014-06-04 2015-03-26 Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол EA032717B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001941.5A EP2952209B1 (en) 2014-06-04 2014-06-04 Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
PCT/EP2015/056524 WO2015185238A1 (en) 2014-06-04 2015-03-26 Homogeneous formulation comprising omega-3 polyunsatured fatty acid and resveratrol for oral administration

Publications (2)

Publication Number Publication Date
EA201692398A1 EA201692398A1 (ru) 2017-04-28
EA032717B1 true EA032717B1 (ru) 2019-07-31

Family

ID=50884651

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692398A EA032717B1 (ru) 2014-06-04 2015-03-26 Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол

Country Status (13)

Country Link
US (1) US10300035B2 (enExample)
EP (1) EP2952209B1 (enExample)
JP (1) JP6552526B2 (enExample)
CN (1) CN106456783B (enExample)
AU (1) AU2015271277A1 (enExample)
CA (1) CA2943000A1 (enExample)
EA (1) EA032717B1 (enExample)
ES (1) ES2666836T3 (enExample)
MX (1) MX361765B (enExample)
PL (1) PL2952209T3 (enExample)
PT (1) PT2952209T (enExample)
UA (1) UA118289C2 (enExample)
WO (1) WO2015185238A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115607677B (zh) * 2022-05-06 2025-08-05 太阳雨林(北京)生物医药有限公司 预防、阻止或治疗微生物感染的复合物及其制备和应用
EP4520348A1 (en) * 2022-05-06 2025-03-12 Sunforest (Beijing) Biopharma Ltd Carbon chain substance for regulating transmembrane transport and fluidity of cell membranes, and preparation and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026666A2 (en) * 1999-10-08 2001-04-19 Sigma-Tau Healthscience S.P.A. Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
WO2011162802A1 (en) * 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
WO2013171204A2 (de) * 2012-05-15 2013-11-21 F. Holzer Gmbh Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
DE602005026582D1 (de) * 2005-03-11 2011-04-07 Recon Oil Ind Private Ltd Synergistisch hitzestabiles ölmedium mit eicosapentaensäure (epa) und docosahexaensäure (dha)
DE202008003509U1 (de) * 2008-03-12 2009-10-15 Langhoff, Gertrud Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
EA201200935A1 (ru) 2009-12-23 2012-12-28 Дефианте Фармасеутика С.А. Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
WO2011120530A1 (en) 2010-03-31 2011-10-06 Lifecycle Phama A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
CN102228089B (zh) * 2011-06-22 2013-02-20 刘升胜 一种天然复合食用植物健脑营养饮料
KR101418980B1 (ko) * 2012-04-24 2014-07-11 (주)바이오제닉스 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026666A2 (en) * 1999-10-08 2001-04-19 Sigma-Tau Healthscience S.P.A. Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
WO2011162802A1 (en) * 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
WO2013171204A2 (de) * 2012-05-15 2013-11-21 F. Holzer Gmbh Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Also Published As

Publication number Publication date
US20170119720A1 (en) 2017-05-04
JP2017516820A (ja) 2017-06-22
US10300035B2 (en) 2019-05-28
MX2016013190A (es) 2017-01-09
EA201692398A1 (ru) 2017-04-28
EP2952209A1 (en) 2015-12-09
EP2952209B1 (en) 2018-03-28
AU2015271277A1 (en) 2016-11-10
CN106456783A (zh) 2017-02-22
PT2952209T (pt) 2018-05-09
JP6552526B2 (ja) 2019-07-31
ES2666836T3 (es) 2018-05-08
CA2943000A1 (en) 2015-12-10
MX361765B (es) 2018-12-17
WO2015185238A1 (en) 2015-12-10
CN106456783B (zh) 2020-06-12
UA118289C2 (uk) 2018-12-26
PL2952209T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
JP7199389B2 (ja) 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
JP6896019B2 (ja) 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
US20180015038A1 (en) Omega-3 fatty acid self-emulsifying composition
BRPI0415744B1 (pt) uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional
US10064888B2 (en) Pectin based nanoparticles
KR20230004545A (ko) Lpc-dha 및 lpc-epa가 풍부한 크릴 오일 조성물
ES2889874T3 (es) Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas
US12605411B2 (en) Phospholipid compositions for delivery of therapeutic compounds
JP2025502795A (ja) Ｅｐａ－ｅｅナノ脂質組成物、その製剤、調製方法及び使用
JP6552526B2 (ja) ω−３多価不飽和脂肪酸及びレスベラトロールを含む経口投与用均質処方物
WO2014095628A1 (en) Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
CN116407502B (zh) 高epa含量的口服微乳及其制备方法和应用
CN106456587B (zh) 含有欧米茄-3和白藜芦醇的固体制剂

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM